Automated Detection of Residual Cells After Sex-mismatched Stem-cell Transplantation - Evidence for Presence of Disease-marker Negative Residual Cells

Overview

Journal Mol Cytogenet

Publisher Biomed Central

Specialty Biochemistry

Date 2009 Jun 2

PMID 19480690

Citations 2

Authors

Jorn Erlecke

Isabell Hartmann

Martin Hoffmann

Torsten Kroll

Heike Starke

Anita Heller

Alexander Gloria

Herbert G Sayer

Tilman Johannes

Uwe Claussen

Thomas Liehr

Ivan F Loncarevic

Affiliations

Soon will be listed here.

Abstract

Background: A new chimerism analysis based on automated interphase fluorescence in situ hybridization (FISH) evaluation was established to detect residual cells after allogene sex-mismatched bone marrow or blood stem-cell transplantation.Cells of 58 patients were characterized as disease-associated due to presence of a bcr/abl-gene-fusion or a trisomy 8 and/or a simultaneous hybridization of gonosome-specific centromeric probes. The automatic slide scanning platform Metafer with its module MetaCyte was used to analyse 3,000 cells per sample.

Results: Overall 454 assays of 58 patients were analyzed. 13 of 58 patients showed residual recipient cells at one stage of more than 4% and 12 of 58 showed residual recipient cells less than 4%, respectively. As to be expected, patients of the latter group were associated with a higher survival rate (48 vs. 34 month). In only two of seven patients with disease-marker positive residual cells between 0.1-1.3% a relapse was observed. Besides, disease-marker negative residual cells were found in two patients without relapse at a rate of 2.8% and 3.3%, respectively.

Conclusion: The definite origin and meaning of disease-marker negative residual cells is still unclear. Overall, with the presented automatic chimerism analysis of interphase FISH slides, a sensitive method for detection of disease-marker positive residual cells is on hand.

Citing Articles

Amenorrhoea with XY karyotype postbone marrow transplant.

Tambawala Z, Al Ani K, Abdelgadir E, Alawadi F BMJ Case Rep. 2021; 14(2).

PMID: 33547101 PMC: 7871276. DOI: 10.1136/bcr-2020-239767.

Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines.

Vives J, Casademont-Roca A, Martorell L, Nogues N Bone Marrow Transplant. 2020; 55(7):1229-1239.

PMID: 32024991 DOI: 10.1038/s41409-020-0822-8.

References

Cilloni D, Guerrasio A, Giugliano E, Scaravaglio P, Volpe G, Rege-Cambrin G . From genes to therapy: the case of Philadelphia chromosome-positive leukemias. Ann N Y Acad Sci. 2002; 963:306-12. DOI: 10.1111/j.1749-6632.2002.tb04122.x. View

Muhlmann J, Thaler J, Hilbe W, Bechter O, Erdel M, Utermann G . Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer. 1998; 21(2):90-100. DOI: 10.1002/(sici)1098-2264(199802)21:2<90::aid-gcc3>3.0.co;2-2. View

Udayakumar A, Pathare A, Al-Kindi S, Khan H, Rehmen J, Zia F . Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia. Cancer Genet Cytogenet. 2007; 177(2):89-94. DOI: 10.1016/j.cancergencyto.2007.05.014. View

Buno I, Anta B, Moreno-Lopez E, Balsalobre P, Balas A, Garcia-Sanchez F . Lineage-specific chimaerism quantification after T-cell depleted peripheral blood stem cell transplantation. Leuk Lymphoma. 2003; 44(4):659-67. DOI: 10.1080/1042819031000067738. View

Thiele J, Wickenhauser C, Kvasnicka H, Varus E, Kleppe S, Beelen D . Mixed chimerism of bone marrow CD34+ progenitor cells (genotyping, bcr/abl analysis) after allogeneic transplantation for chronic myelogenous leukemia. Transplantation. 2002; 74(7):982-6. DOI: 10.1097/00007890-200210150-00015. View

Shimoni A, Nagler A, Kaplinsky C, Reichart M, Avigdor A, Hardan I . Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia. 2002; 16(8):1413-8; discussion 1419-22. DOI: 10.1038/sj.leu.2402581. View

Nagler A, Slavin S, Yarkoni S, Fejgin M, Amiel A . Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization. Cancer Genet Cytogenet. 1994; 73(2):130-3. DOI: 10.1016/0165-4608(94)90196-1. View

Adams K, Lambert N, Heimfeld S, Tylee T, Pang J, Erickson T . Male DNA in female donor apheresis and CD34-enriched products. Blood. 2003; 102(10):3845-7. DOI: 10.1182/blood-2003-05-1570. View

Chase A, Grand F, Zhang J, Blackett N, Goldman J, Gordon M . Factors influencing the false positive and negative rates of BCR-ABL fluorescence in situ hybridization. Genes Chromosomes Cancer. 1997; 18(4):246-53. View

10.

Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer H . Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003; 82(6):336-42. DOI: 10.1007/s00277-003-0654-9. View

11.

Carothers A . Counting, measuring, and mapping in FISH-labelled cells: sample size considerations and implications for automation. Cytometry. 1994; 16(4):298-304. DOI: 10.1002/cyto.990160403. View

12.

Dubovsky J, Daxberger H, Fritsch G, Printz D, Peters C, Matthes S . Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection. Leukemia. 1999; 13(12):2059, 2060-9. View

13.

Tanaka K, Arif M, Eguchi M, Kumaravel T, Ueda R, Ohno R . Application of fluorescence in situ hybridization to detect residual leukemic cells with 9;22 and 15;17 translocations. Leukemia. 1997; 11(3):436-40. DOI: 10.1038/sj.leu.2400583. View

14.

Tamura S, Saheki K, Takatsuka H, Wada H, Fujimori Y, Okamoto T . Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies. Ann Hematol. 2000; 79(11):622-6. DOI: 10.1007/s002770000204. View

15.

Bader P, Beck J, Frey A, Schlegel P, Hebarth H, Handgretinger R . Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant. 1998; 21(5):487-95. DOI: 10.1038/sj.bmt.1701119. View

16.

Palka G, Stuppia L, Di Bartolomeo P, Morizio E, Peila R, Franchi P . FISH detection of mixed chimerism in 33 patients submitted to bone marrow transplantation. Bone Marrow Transplant. 1996; 17(2):231-6. View

17.

Hancock J, Goulden N, Oakhill A, Steward C . Quantitative analysis of chimerism after allogeneic bone marrow transplantation using immunomagnetic selection and fluorescent microsatellite PCR. Leukemia. 2003; 17(1):247-51. DOI: 10.1038/sj.leu.2402759. View

18.

Schattenberg A, de Witte T, Salden M, Vet J, van Dijk B, Smeets D . Mixed hematopoietic chimerism after allogeneic transplantation with lymphocyte-depleted bone marrow is not associated with a higher incidence of relapse. Blood. 1989; 73(5):1367-72. View

19.

Mattsson J, Uzunel M, Tammik L, Aschan J, Ringden O . Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. Leukemia. 2001; 15(12):1976-85. DOI: 10.1038/sj.leu.2402311. View

20.

Kajtar B, Mehes G, Lorch T, Deak L, Kneifne M, Alpar D . Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei. Cytometry A. 2006; 69(6):506-14. DOI: 10.1002/cyto.a.20260. View